TriangleNCT00027560 · STUDY IN CONTEXT
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- trial label
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0000
- source section id
- NCT00027560-om-0000
- source outcome index
- 0
- endpoint
- Overall Survival
- endpoint definition
- Overall Survival
- time origin
- 12 months post transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Population is defined as all participants who received transplant as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0001
- source section id
- NCT00027560-om-0001
- source outcome index
- 1
- endpoint
- Overall Survival
- endpoint definition
- Overall Survival
- time origin
- 24 months post transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Population is defined as all participants who received transplant as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0002
- source section id
- NCT00027560-om-0002
- source outcome index
- 2
- endpoint
- Acute Graft-versus-Host Disease Matched Related Patients
- endpoint definition
- Grade III-IV Acute Graft-versus-Host Disease
- time origin
- up to 4 months post transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The number of matched related patients was analyzed as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0003
- source section id
- NCT00027560-om-0003
- source outcome index
- 3
- endpoint
- Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients
- endpoint definition
- Grade III-IV Acute Graft-versus-Host Disease
- time origin
- up to 4 months post transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The number of unrelated and mismatched patients was analyzed as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0004
- source section id
- NCT00027560-om-0004
- source outcome index
- 4
- endpoint
- Extensive Chronic Graft-versus-Host Disease Matched Related Patients
- endpoint definition
- Extensive Chronic Graft-versus-Host Disease Matched Related Patients
- time origin
- up to 2 years post transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The number of matched related patients was analyzed as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0005
- source section id
- NCT00027560-om-0005
- source outcome index
- 5
- endpoint
- Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients
- endpoint definition
- Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients
- time origin
- up to 2 years post transplant
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- The number of unrelated and mismatched patients was analyzed as per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0000
- arm key
- OG000
- arm label
- TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES
- regimen
- This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
- analyzed count
- 50
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0001
- arm key
- OG000
- arm label
- TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES
- regimen
- This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
- analyzed count
- 50
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Matched Related Patients
- regimen
- Matched Related Patients
- analyzed count
- 25
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Unrelated and Mismatched Related Patients
- regimen
- Unrelated and Mismatched Related Patients
- analyzed count
- 25
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0004
- arm key
- OG000
- arm label
- Matched Related Patients
- regimen
- Matched Related Patients
- analyzed count
- 25
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- outcome key
- om-0005
- arm key
- OG000
- arm label
- Unrelated and Mismatched Related Patients
- regimen
- Unrelated and Mismatched Related Patients
- analyzed count
- 25
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00027560-om-0005#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-multiple-myeloma
- nct id
- NCT00027560
- harm key
- EG000
- source section id
- NCT00027560-ae
- event group key
- EG000
- event group label
- TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES
- serious affected
- 3
- serious at risk
- 50
- other affected
- 43
- other at risk
- 50
- frequency threshold
- 5
- collection period
- Weekly during the first 3 months post transplant, every 6 weeks during months 3-6 and then 3 month intervals for 1 year post transplant
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice